MED17 and breast cancer: In this study, a novel 8-DRG signature (MDC1, RPA3, MED17, DDB2, SFPQ, XRCC4, CYP19A1, and PARP3) was successfully identified to predict the survival of patients with BC in both the training and test cohorts.